Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free CRMD Stock Alerts

CorMedix (CRMD) Financials

CorMedix logo
$7.78 +0.23 (+2.98%)
As of 02:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for CorMedix

Annual Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -21 -18 -25 -33 -27 -44 -22 -28 -30 -46 -18
Consolidated Net Income / (Loss)		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Net Income / (Loss) Continuing Operations		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Total Pre-Tax Income 		-20 -18 -25 -33 -27 -21 -27 -29 -30 -46 -19
Total Operating Income		 -8.90 -17 -25 -33 -27 -21 -27 -29 -31 -49 -22
Total Gross Profit		 -0.26 -0.11 -0.14 0.21 0.03 -0.09 0.03 0.04 0.06 0.00 40
Total Revenue		 0.19 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43
Operating Revenue		 0.19 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43
Total Cost of Revenue		 -0.45 -0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.19
Operating Cost of Revenue		 0.45 0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.19
Total Operating Expenses		 8.65 17 25 33 27 21 27 29 31 49 63
Selling, General & Admin Expense		 7.33 10 8.88 8.65 8.07 9.87 14 16 20 18 30
Marketing Expense		 - - - - - - - - - 18 29
Research & Development Expense		 1.32 6.28 16 24 19 11 13 13 11 13 3.94
Total Other Income / (Expense), net		 -12 -1.53 0.12 -0.17 0.03 -0.49 0.11 -0.02 0.34 2.62 3.03
Interest Expense		 2.46 0.00 0.00 0.01 0.00 0.79 0.03 0.02 0.03 0.03 0.04
Interest & Investment Income		 -0.09 0.06 0.13 0.11 0.03 0.32 0.12 0.01 0.33 2.68 2.58
Other Income / (Expense), net		 -9.00 -1.59 -0.01 -0.28 -0.00 -0.02 0.02 -0.02 0.04 -0.03 0.49
Income Tax Expense		 - - - - 0.00 -5.06 -5.17 -1.25 -0.59 0.00 -1.39
Basic Earnings per Share		 ($0.96) ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30)
Weighted Average Basic Shares Outstanding		 21.44M 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 40.27M 50.90M 58.87M
Diluted Earnings per Share		 ($0.96) ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) - - ($0.91) ($0.30)
Weighted Average Diluted Shares Outstanding		 21.44M 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 44.50M 50.90M 58.87M

Quarterly Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -11 -9.75 -15 -14 -14 -2.78 13 21 20 109
Consolidated Net Income / (Loss)		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Net Income / (Loss) Continuing Operations		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Total Pre-Tax Income 		-11 -11 -9.74 -15 -16 -14 -2.78 13 21 20 53
Total Operating Income		 -11 -12 -10 -16 -17 -15 -3.29 13 20 20 51
Total Gross Profit		 0.00 0.00 0.00 - -0.82 0.30 11 30 37 38 93
Total Revenue		 0.00 0.00 0.00 - 0.00 0.81 11 31 39 40 101
Operating Revenue		 0.00 0.00 0.00 - 0.00 0.81 11 31 39 40 101
Total Cost of Revenue		 0.00 0.00 0.00 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57
Operating Cost of Revenue		 0.00 0.00 0.00 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57
Total Operating Expenses		 11 12 10 16 16 16 14 17 17 18 42
Selling, General & Admin Expense		 7.61 3.75 3.74 2.58 8.71 7.56 6.58 0.77 9.69 9.50 25
Marketing Expense		 - 3.26 4.06 - 6.34 7.39 6.75 - 4.47 6.38 11
Research & Development Expense		 3.41 4.79 2.66 2.29 0.84 0.65 0.73 1.73 3.19 2.44 5.10
Total Other Income / (Expense), net		 0.45 0.53 0.72 0.91 0.84 1.15 0.51 1.03 0.52 0.81 1.23
Interest Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.95
Interest & Investment Income		 0.45 0.55 0.77 0.92 0.86 0.66 0.55 0.51 0.57 0.83 1.56
Other Income / (Expense), net		 0.01 -0.01 -0.03 0.00 -0.00 0.50 -0.03 0.53 -0.04 -0.02 0.62
Income Tax Expense		 0.00 0.00 0.00 - -1.39 0.00 0.00 - 0.00 0.52 -56
Basic Earnings per Share		 ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42
Weighted Average Basic Shares Outstanding		 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M
Diluted Earnings per Share		 - - ($0.17) - ($0.25) ($0.25) ($0.05) - $0.30 $0.28 $1.26
Weighted Average Diluted Shares Outstanding		 45.38M 54.81M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 68.98M 71.92M 86.21M
Weighted Average Basic & Diluted Shares Outstanding		 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M

Annual Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1.97 7.48 -3.75 2.32 7.24 -1.27 26 11 -10 0.45 -3.07
Net Cash From Operating Activities		 -6.32 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51
Net Cash From Continuing Operating Activities		 -6.32 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51
Net Income / (Loss) Continuing Operations		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Consolidated Net Income / (Loss)		 -20 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18
Depreciation Expense		 0.02 0.02 0.03 0.04 0.07 0.07 0.13 0.06 0.08 0.07 0.15
Amortization Expense		 - - - 0.00 0.00 0.31 0.03 0.12 0.12 0.13 0.30
Non-Cash Adjustments To Reconcile Net Income		 15 5.64 2.59 1.51 1.11 2.54 0.66 5.05 4.07 5.49 6.13
Changes in Operating Assets and Liabilities, net		 -0.52 0.01 -0.23 2.88 1.94 -1.54 -0.76 1.84 1.07 2.23 -39
Net Cash From Investing Activities		 -0.03 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21
Net Cash From Continuing Investing Activities		 -0.03 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21
Purchase of Property, Plant & Equipment		 -0.03 -0.02 -0.06 -0.15 -0.05 -0.04 -0.11 -1.43 -0.22 -0.33 -0.12
Purchase of Investments		 0.00 -24 0.00 -13 0.00 -14 -8.55 - -31 -77 -27
Sale and/or Maturity of Investments		 - - 11 24 1.60 2.12 16 -7.71 28 60 48
Net Cash From Financing Activities		 8.36 44 7.09 21 29 26 40 42 18 56 26
Net Cash From Continuing Financing Activities		 8.36 44 7.09 21 30 26 40 42 18 56 26
Issuance of Common Equity		 6.72 28 6.23 19 22 15 40 41 18 56 19
Other Financing Activities, net		 0.32 15 0.86 0.01 0.04 8.80 0.41 0.30 0.13 0.09 7.44
Effect of Exchange Rate Changes		 -0.05 -0.02 0.00 0.02 -0.01 -0.00 0.01 -0.01 -0.01 0.00 -0.00
Cash Interest Paid		 0.00 0.00 0.00 0.01 0.00 0.01 0.03 0.02 0.03 0.03 0.04

Quarterly Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Change in Cash & Equivalents		 -18 -5.61 34 -9.68 -8.46 -6.71 6.75 5.36 26 93 -110
Net Cash From Operating Activities		 -10 -8.57 -8.70 -11 -17 -14 -14 -5.61 20 30 31
Net Cash From Continuing Operating Activities		 -10 -8.57 -8.70 -11 -17 -14 -14 -5.75 20 30 31
Net Income / (Loss) Continuing Operations		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Consolidated Net Income / (Loss)		 -11 -11 -9.74 -15 -14 -14 -2.78 13 21 20 109
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.08 0.11 0.11 0.16
Amortization Expense		 0.03 0.03 0.03 0.03 0.04 0.09 0.09 0.09 0.09 0.09 3.55
Non-Cash Adjustments To Reconcile Net Income		 2.22 1.06 1.00 1.22 2.44 1.26 1.23 1.19 3.50 2.68 1.20
Changes in Operating Assets and Liabilities, net		 -2.09 1.59 -0.01 2.74 -5.35 -1.27 -12 -21 -4.62 7.29 -83
Net Cash From Investing Activities		 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.19 -20 -291
Net Cash From Continuing Investing Activities		 -15 -2.39 -0.59 0.60 8.94 6.27 6.32 -0.30 -0.19 -20 -291
Purchase of Property, Plant & Equipment		 -0.01 -0.01 -0.01 -0.30 -0.06 -0.03 -0.01 -0.01 -0.01 -0.02 -0.51
Purchase of Investments		 -25 -17 -18 -16 -7.69 -12 -1.67 -5.29 -9.98 -28 -15
Sale and/or Maturity of Investments		 11 15 18 17 17 18 8.00 5.00 9.80 8.10 34
Net Cash From Financing Activities		 7.20 5.35 43 0.47 -0.10 1.06 14 11 6.09 83 151
Net Cash From Continuing Financing Activities		 7.20 5.35 43 0.47 -0.10 1.06 14 11 6.09 83 151
Issuance of Common Equity		 - - 43 0.43 0.00 - 12 5.51 6.76 82 0.00
Other Financing Activities, net		 7.20 -7.16 0.02 0.03 -0.10 0.05 1.71 5.78 -0.67 0.88 0.86

Annual Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 5.10 37 22 13 19 29 49 69 62 82 119
Total Current Assets		 5.04 37 22 13 19 29 48 66 60 79 115
Cash & Equivalents		 4.34 12 8.06 10 18 16 42 53 43 44 41
Short-Term Investments		 0.00 24 12 1.60 0.00 12 4.44 12 16 32 11
Accounts Receivable		 0.08 0.32 0.01 0.06 0.01 0.00 0.00 0.05 - 0.00 52
Inventories, net		 0.46 0.38 0.17 0.59 0.43 0.34 0.14 0.00 0.00 2.11 7.60
Prepaid Expenses		 0.16 0.81 1.32 0.45 0.43 0.48 1.47 0.82 0.63 1.24 3.63
Plant, Property, & Equipment, net		 0.04 0.04 0.07 0.19 0.16 0.12 0.11 1.47 1.61 1.87 1.83
Total Noncurrent Assets		 0.02 0.01 0.01 0.00 0.00 0.00 1.01 1.00 0.88 0.74 2.44
Long-Term Investments		 - - - - - - - 0.10 0.10 0.10 0.11
Noncurrent Note & Lease Receivables		 - - - - - - - - - - 0.00
Goodwill		 - - - - - - - - - - 0.00
Intangible Assets		 - - - - - - - - - 0.00 1.84
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - - 0.00
Other Noncurrent Operating Assets		 0.02 0.01 0.01 - 0.00 0.00 1.01 0.90 0.78 0.64 0.49
Total Liabilities & Shareholders' Equity		 5.10 37 22 13 19 29 49 69 62 82 119
Total Liabilities		 1.46 3.09 4.09 6.26 14 5.83 5.09 6.15 6.98 12 34
Total Current Liabilities		 1.43 3.06 4.09 6.26 7.77 5.83 4.16 5.35 6.31 11 34
Accounts Payable		 0.89 1.71 1.65 1.81 2.59 1.02 1.13 2.21 2.20 4.28 1.72
Accrued Expenses		 0.52 1.22 2.34 4.36 5.17 4.80 2.92 3.01 3.97 6.97 32
Other Current Liabilities		 - - - - - 0.00 0.11 0.12 0.13 0.15 0.17
Total Noncurrent Liabilities		 0.04 0.03 0.00 0.00 6.13 0.00 0.92 0.80 0.67 0.52 0.35
Capital Lease Obligations		 - - - - - - - - - - 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 - - - - 0.00 0.00 0.92 0.80 0.67 0.52 0.35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Total Preferred & Common Equity		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.63 34 18 7.19 4.93 24 44 63 55 70 85
Common Stock		 80 128 137 159 184 219 262 308 330 392 424
Retained Earnings		 -76 -94 -119 -152 -179 -195 -217 -246 -275 -322 -340
Accumulated Other Comprehensive Income / (Loss)		 0.10 0.06 0.08 0.10 0.10 0.10 0.10 0.09 0.08 0.09 0.09

Quarterly Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 68 62 59 57 91 68 58 78 150 253 751
Total Current Assets		 65 60 57 55 89 63 53 73 145 248 260
Cash & Equivalents		 49 43 25 20 53 35 29 35 66 159 48
Short-Term Investments		 16 16 30 33 33 23 17 11 11 31 7.22
Accounts Receivable		 0.00 0.00 - - - - 0.21 17 55 43 159
Inventories, net		 0.00 0.00 - - - 2.32 4.01 6.65 7.49 9.63 29
Prepaid Expenses		 0.61 0.55 1.05 2.14 2.39 2.46 3.37 3.09 5.26 4.80 16
Plant, Property, & Equipment, net		 1.45 1.50 1.61 1.60 1.59 1.91 1.92 1.90 1.73 1.64 7.52
Total Noncurrent Assets		 0.94 0.91 0.84 0.81 0.78 2.71 2.62 2.53 2.99 2.90 484
Long-Term Investments		 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.11 0.11 0.11 23
Noncurrent Note & Lease Receivables		 - - - - - - - - - - 0.86
Goodwill		 - - - - - - - - - - 18
Intangible Assets		 - - - - - 2.00 1.95 1.90 1.79 1.74 390
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - - 53
Total Liabilities & Shareholders' Equity		 68 62 59 57 91 68 58 78 150 253 751
Total Liabilities		 6.01 5.76 5.31 7.98 8.23 10 12 19 35 32 377
Total Current Liabilities		 5.27 5.06 4.67 7.39 7.67 9.53 11 18 34 32 134
Short-Term Debt		 - - - - - - - - - - 0.84
Accounts Payable		 2.50 1.77 1.45 2.90 2.39 2.83 3.34 1.34 1.93 5.82 20
Accrued Expenses		 2.65 3.16 3.09 4.34 5.14 6.55 7.61 17 32 26 109
Other Current Liabilities		 0.13 0.13 0.14 0.14 0.15 0.15 0.16 0.16 0.17 0.18 3.25
Total Noncurrent Liabilities		 0.74 0.70 0.63 0.59 0.56 0.48 0.44 0.39 0.30 0.26 243
Capital Lease Obligations		 0.74 0.70 - 0.59 0.56 0.48 - - - - 2.97
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 145
Other Noncurrent Operating Liabilities		 - - 0.63 - - - 0.44 0.39 0.30 0.26 96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 62 56 54 49 83 58 46 59 115 221 374
Total Preferred & Common Equity		 62 56 54 49 83 58 46 59 115 221 374
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 62 56 54 49 83 58 46 59 115 221 374
Common Stock		 322 323 340 346 390 394 396 412 434 520 565
Retained Earnings		 -260 -267 -286 -297 -307 -336 -350 -353 -319 -299 -191
Accumulated Other Comprehensive Income / (Loss)		 0.04 0.05 0.10 0.09 0.08 0.08 0.09 0.09 0.08 0.08 0.09

Annual Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9,358.97% 11.02% 6.65% 46.95% 30.51% -34.09% -15.55% -20.19% -65.74% -100.00% 0.00%
EBITDA Growth		 -354.32% -1.91% -35.74% -34.03% 19.22% 22.95% -30.97% -8.31% -3.74% -60.58% 56.11%
EBIT Growth		 -239.09% -1.91% -35.77% -34.04% 19.09% 21.72% -29.33% -8.32% -3.83% -60.16% 55.36%
NOPAT Growth		 -81.11% -87.08% -48.68% -32.97% 18.41% 21.80% -29.57% -8.14% -4.03% -59.87% 54.34%
Net Income Growth		 -123.95% 11.08% -35.50% -33.95% 18.72% 38.75% -34.04% -28.07% -5.29% -56.02% 61.31%
EPS Growth		 -39.13% 39.58% -12.07% -33.95% 18.72% -19.21% 57.22% 0.00% 0.00% 0.00% 67.03%
Operating Cash Flow Growth		 -74.68% -98.18% -77.74% -28.39% 17.09% 36.49% -45.94% 3.70% -15.13% -57.70% -31.78%
Free Cash Flow Firm Growth		 -706.03% 10.77% -51.21% -25.99% 17.35% 2.66% -30.29% 7.30% -1.79% -57.81% -69.72%
Invested Capital Growth		 89.31% -119.25% -63.17% -96.72% -35.74% 27.80% 52.34% -25.21% -36.42% -53.29% 641.51%
Revenue Q/Q Growth		 77.93% -12.07% 41.43% -8.14% -13.31% -0.61% 0.00% 0.00% -28.98% -100.00% 240.63%
EBITDA Q/Q Growth		 -1.52% -10.00% -12.26% -13.10% 31.67% -57.50% -2.01% -6.27% -2.16% -17.41% 57.74%
EBIT Q/Q Growth		 -1.52% -9.99% -12.27% -13.09% 31.60% -55.84% -2.38% -6.44% -2.16% -17.33% 57.12%
NOPAT Q/Q Growth		 -7.88% -11.21% -11.98% -12.77% 31.60% -55.69% -2.67% -6.11% -2.03% -17.47% 56.13%
Net Income Q/Q Growth		 5.63% -9.99% -12.03% -13.00% 31.71% -82.99% -3.68% -6.43% -1.43% -16.45% 61.15%
EPS Q/Q Growth		 30.43% -87.10% -14.04% -13.00% 31.71% -19.21% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -11.48% -19.69% -14.76% -2.80% 0.32% 18.05% -10.29% 0.30% -1.19% -13.57% 9.20%
Free Cash Flow Firm Q/Q Growth		 -43.69% -17.66% -16.30% 1.77% -22.69% 23.45% -9.60% -3.14% 5.51% -13.40% -6.47%
Invested Capital Q/Q Growth		 -105.92% 5.25% 17.18% -98.16% 58.20% -24.64% 15.81% -5.16% -79.85% -101.22% 161.29%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -135.53% -51.68% -63.62% 65.09% 7.68% -31.76% 14.37% 22.00% 94.29% 0.00% 92.66%
EBITDA Margin		 -9,450.22% -8,675.05% -11,041.03% -10,070.21% -6,233.21% -7,287.37% -11,300.69% -15,335.95% -46,443.53% 0.00% -49.25%
Operating Margin		 -4,703.30% -7,925.56% -11,048.80% -9,997.39% -6,250.44% -7,416.31% -11,378.44% -15,417.51% -46,819.91% 0.00% -51.43%
EBIT Margin		 -9,458.18% -8,682.22% -11,052.45% -10,081.41% -6,250.48% -7,423.78% -11,368.54% -15,428.66% -46,763.12% 0.00% -50.30%
Profit (Net Income) Margin		 -10,806.25% -8,655.37% -10,996.46% -10,023.45% -6,242.40% -5,801.29% -9,207.70% -14,774.70% -45,409.90% 0.00% -41.24%
Tax Burden Percent		 104.56% 103.63% 100.00% 99.74% 100.00% 76.45% 80.99% 95.76% 98.07% 100.00% 92.78%
Interest Burden Percent		 109.27% 96.20% 99.49% 99.68% 99.87% 102.21% 100.00% 100.01% 99.02% 94.60% 88.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -116.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -113.25%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.64%
Return on Equity (ROE)		 10,546.51% -96.62% -95.10% -264.00% -442.46% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -166.09%
Operating Return on Assets (OROA)		 -443.91% -86.47% -83.95% -187.79% -166.45% -87.07% -69.04% -49.82% -46.70% 0.00% -21.77%
Return on Assets (ROA)		 -507.18% -86.20% -83.53% -186.71% -166.23% -68.04% -55.92% -47.71% -45.35% 0.00% -17.85%
Return on Common Equity (ROCE)		 10,595.64% -96.62% -95.10% -263.99% -442.42% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17%
Return on Equity Simple (ROE_SIMPLE)		 -562.76% -53.47% -138.33% -458.89% -543.74% -69.50% -49.81% -44.92% -53.94% -66.06% -21.18%
Net Operating Profit after Tax (NOPAT)		 -6.23 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16
NOPAT Margin		 -3,292.31% -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00%
Net Nonoperating Expense Percent (NNEP)		 -411.46% -32.73% -26.16% -61.33% -67.36% -8.60% -7.92% -13.55% -13.25% -17.85% -3.56%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -48.86% -18.49%
Cost of Revenue to Revenue		 -235.53% -151.68% 163.62% 34.91% 92.32% 131.76% 85.63% 78.00% 5.71% 0.00% 7.34%
SG&A Expenses to Revenue		 3,871.03% 4,884.39% 3,963.79% 2,627.28% 1,878.73% 3,482.59% 5,801.06% 8,561.30% 30,586.61% 0.00% 68.92%
R&D to Revenue		 696.73% 2,989.49% 7,021.40% 7,435.20% 4,379.39% 3,901.95% 5,591.75% 6,878.21% 16,327.59% 0.00% 9.07%
Operating Expenses to Revenue		 4,567.77% 7,873.88% 10,985.19% 10,062.48% 6,258.12% 7,384.55% 11,392.81% 15,439.51% 46,914.20% 0.00% 144.09%
Earnings before Interest and Taxes (EBIT)		 -18 -18 -25 -33 -27 -21 -27 -29 -31 -49 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -18 -25 -33 -27 -21 -27 -29 -30 -49 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 11.27 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.63
Price to Tangible Book Value (P/TBV)		 11.27 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.76
Price to Revenue (P/Rev)		 216.37 302.80 259.21 420.26 267.38 620.71 887.07 897.58 2,871.04 0.00 10.97
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.93
Enterprise Value to Revenue (EV/Rev)		 193.45 133.59 168.46 383.36 240.22 520.07 692.53 553.49 1,968.73 0.00 9.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 17.82 -1.06 -1.08 -1.30 -1.96 -1.41 -1.11 -1.05 -1.06 -1.08 -0.83
Leverage Ratio		 -20.79 1.12 1.14 1.41 2.66 1.69 1.16 1.11 1.11 1.15 1.30
Compound Leverage Factor		 -22.72 1.08 1.13 1.41 2.66 1.73 1.16 1.11 1.10 1.09 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.03% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.97% 100.00% 100.00% 99.99% 44.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.62 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -14.84 8.27 -1.85 -10.06 -12.34 7.43 18.12 11.40 9.34 3.17 4.94
Noncontrolling Interest Sharing Ratio		 -0.47% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.53 12.11 5.34 2.12 2.40 5.04 11.58 12.44 9.44 6.97 3.39
Quick Ratio		 3.10 11.66 4.93 1.92 2.27 4.86 11.14 12.26 9.32 6.67 3.05
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -11 -16 -21 -17 -17 -22 -20 -20 -32 -55
Operating Cash Flow to CapEx		 -24,883.15% -81,101.24% -37,915.97% -18,808.84% -48,474.35% -41,158.36% -19,502.87% -1,484.23% -11,103.54% -11,735.25% -43,735.12%
Free Cash Flow to Firm to Interest Expense		 -4.92 -2,728.80 -12,476.03 -3,667.41 -9,093.13 -21.05 -650.09 -1,255.85 -768.62 -937.74 -1,499.31
Operating Cash Flow to Interest Expense		 -2.56 -3,160.17 -16,983.52 -5,087.59 -12,653.80 -19.11 -661.16 -1,326.93 -918.60 -1,119.94 -1,390.32
Operating Cash Flow Less CapEx to Interest Expense		 -2.57 -3,164.06 -17,028.31 -5,114.64 -12,679.90 -19.16 -664.55 -1,416.33 -926.88 -1,129.48 -1,393.50
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.01 0.01 0.02 0.03 0.01 0.01 0.00 0.00 0.00 0.43
Accounts Receivable Turnover		 4.59 1.06 1.37 8.65 11.45 51.79 141.06 7.84 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 1.35 0.30 0.78 0.97 0.85 2.03 0.00 0.00 0.66
Fixed Asset Turnover		 4.88 5.30 4.17 2.57 2.48 2.00 2.05 0.24 0.04 0.00 23.54
Accounts Payable Turnover		 0.00 0.00 0.22 0.07 0.18 0.21 0.19 0.09 0.00 0.00 1.06
Days Sales Outstanding (DSO)		 79.57 343.89 266.93 42.21 31.87 7.05 2.59 46.57 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 270.41 1,207.94 470.39 375.03 429.45 179.60 0.00 0.00 555.18
Days Payable Outstanding (DPO)		 0.00 0.00 1,669.69 5,482.44 2,022.51 1,766.77 1,917.59 4,089.77 215,622.77 0.00 343.19
Cash Conversion Cycle (CCC)		 79.57 343.89 -1,132.35 -4,232.30 -1,520.25 -1,384.69 -1,485.55 -3,863.60 -215,622.77 0.00 211.99
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.71 -1.55 -2.52 -4.96 -6.74 -4.86 -2.32 -2.90 -3.96 -6.07 33
Invested Capital Turnover		 -0.05 -0.19 -0.11 -0.09 -0.07 -0.05 -0.07 -0.07 -0.02 0.00 3.24
Increase / (Decrease) in Invested Capital		 5.89 -0.84 -0.98 -2.44 -1.77 1.87 2.55 -0.58 -1.06 -2.11 39
Enterprise Value (EV)		 37 28 38 126 103 147 166 106 129 115 425
Market Capitalization		 41 64 58 138 115 176 212 171 188 191 477
Book Value per Share		 $0.16 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.44
Tangible Book Value per Share		 $0.16 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.41
Total Capital		 3.63 34 18 7.19 11 24 44 63 55 70 85
Total Debt		 0.00 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.34 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52
Capital Expenditures (CapEx)		 0.03 0.02 0.06 0.15 0.05 0.04 0.11 1.43 0.22 0.33 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.73 -1.56 -2.60 -5.15 -6.90 -4.99 -2.52 -4.47 -5.68 -8.06 29
Debt-free Net Working Capital (DFNWC)		 3.61 34 18 7.01 11 24 44 61 53 68 81
Net Working Capital (NWC)		 3.61 34 18 7.01 11 24 44 61 53 68 81
Net Nonoperating Expense (NNE)		 14 6.53 7.31 9.96 8.02 1.73 2.97 7.60 8.26 12 2.28
Net Nonoperating Obligations (NNO)		 -4.34 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.03 0.04 0.07 0.39 0.16 0.18 0.21 0.21 0.46
Debt-free, Cash-free Net Working Capital to Revenue		 -384.08% -742.33% -1,158.89% -1,563.31% -1,604.59% -1,760.62% -1,053.49% -2,343.31% -8,678.15% 0.00% 66.82%
Debt-free Net Working Capital to Revenue		 1,908.65% 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72%
Net Working Capital to Revenue		 1,908.65% 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30)
Adjusted Weighted Average Basic Shares Outstanding		 4.82M 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 40.27M 50.90M 58.87M
Adjusted Diluted Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 ($0.30)
Adjusted Weighted Average Diluted Shares Outstanding		 4.82M 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 44.50M 54.98M 58.87M
Adjusted Basic & Diluted Earnings per Share		 ($4.80) ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.29M 6.27M 7.59M 11.03M 89.08M 24.15M 28.56M 37.67M 44.50M 54.98M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -6.23 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16
Normalized NOPAT Margin		 -3,292.31% -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00%
Pre Tax Income Margin		 -10,335.19% -8,352.02% -10,996.46% -10,049.50% -6,242.40% -7,587.87% -11,368.54% -15,429.47% -46,305.23% 0.00% -44.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.26 -4,602.41 -18,893.28 -5,908.67 -14,342.97 -26.70 -818.55 -1,847.76 -1,153.57 -1,428.35 -600.66
NOPAT to Interest Expense		 -2.53 -2,940.91 -13,220.93 -4,101.60 -10,040.01 -18.67 -573.48 -1,292.50 -808.48 -999.26 -429.87
EBIT Less CapEx to Interest Expense		 -7.27 -4,606.31 -18,938.07 -5,935.72 -14,369.07 -26.75 -821.94 -1,937.16 -1,161.84 -1,437.90 -603.84
NOPAT Less CapEx to Interest Expense		 -2.54 -2,944.81 -13,265.73 -4,128.65 -10,066.11 -18.72 -576.87 -1,381.90 -816.75 -1,008.80 -433.05
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -1.38% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,829.40% 778.54%
EBITDA Growth		 -56.69% -44.91% -51.68% -86.34% -51.99% -29.08% 69.31% 187.33% 221.84% 234.32% 1,836.63%
EBIT Growth		 -56.26% -44.61% -51.28% -85.77% -51.83% -29.48% 68.36% 185.94% 220.22% 231.92% 1,664.87%
NOPAT Growth		 -56.66% -43.25% -50.35% -86.77% -51.62% -29.62% 68.59% 217.94% 272.11% 277.79% 4,707.41%
Net Income Growth		 -50.23% -48.24% -42.18% -79.73% -36.90% -25.53% 71.50% 191.26% 242.71% 240.11% 4,009.63%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 70.59% 0.00% 220.00% 212.00% 2,620.00%
Operating Cash Flow Growth		 -54.11% -56.94% -45.07% -74.59% -66.54% -63.78% -56.94% 47.75% 214.02% 313.62% 326.06%
Free Cash Flow Firm Growth		 -160.70% -56.32% -19.89% -83.95% -72.13% -83.70% -174.78% -193.47% -30.28% 27.07% -909.86%
Invested Capital Growth		 2.34% -24.23% -37.01% -53.29% 87.29% 115.93% 517.02% 641.51% 15,531.26% 6,253.91% 2,279.74%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 777.11% 168.07% 27.26% 1.68% 153.28%
EBITDA Q/Q Growth		 -30.74% -7.41% 11.24% -49.49% -6.64% 8.78% 78.89% 525.33% 48.78% -2.75% 182.19%
EBIT Q/Q Growth		 -30.49% -7.39% 11.18% -49.26% -6.64% 8.41% 78.30% 505.46% 49.19% -2.79% 166.11%
NOPAT Q/Q Growth		 -31.33% -7.15% 11.33% -49.69% -6.61% 8.40% 78.52% 662.16% 55.58% -5.38% 456.76%
Net Income Q/Q Growth		 -28.73% -6.68% 13.57% -51.41% 1.95% 2.18% 80.38% 584.89% 53.32% -3.95% 447.52%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.67% 350.00%
Operating Cash Flow Q/Q Growth		 -68.87% 17.52% -1.46% -23.55% -61.09% 18.89% 2.78% 58.87% 451.53% 51.96% 2.88%
Free Cash Flow Firm Q/Q Growth		 -61.09% 0.89% 15.30% -36.02% -50.74% -5.78% -26.69% -45.28% 33.08% 40.78% -1,654.24%
Invested Capital Q/Q Growth		 51.97% -54.87% -2.42% -101.22% 96.02% 294.22% 2,580.55% 161.29% 13.44% -20.03% 903.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 22.68% 94.01% 97.80% 95.91% 95.31% 92.48%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,162.91% -27.98% 44.40% 51.91% 49.65% 55.32%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.47% -28.70% 42.12% 51.50% 49.18% 51.02%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,171.59% -28.99% 43.84% 51.40% 49.14% 51.63%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 49.90% 107.87%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 91.21% 100.00% 100.00% 100.00% 100.00% 97.44% 206.49%
Interest Burden Percent		 96.02% 95.39% 92.83% 94.17% 94.93% 92.48% 83.62% 100.00% 102.77% 104.21% 101.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.56% -106.49%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -53.62% 136.68% 229.55% 384.50% 142.31%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -52.90% 135.86% 228.79% 383.83% 138.11%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 49.34% -112.34% -179.78% -340.27% -38.59%
Return on Equity (ROE)		 -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -9,401.45% -407.60% -166.09% -61.83% 128.63% -82.67%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -26.67% -4.38% 18.97% 39.00% 38.47% 26.26%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -24.66% -3.66% 18.97% 40.08% 39.07% 54.86%
Return on Common Equity (ROCE)		 -58.41% -66.62% -57.05% -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72%
Return on Equity Simple (ROE_SIMPLE)		 -61.63% -75.23% -47.83% 0.00% -86.60% -115.01% -78.60% 0.00% 14.95% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 13 20 19 106
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 42.12% 51.50% 47.92% 105.34%
Net Nonoperating Expense Percent (NNEP)		 -4.85% -5.19% -3.34% -5.60% -4.86% -7.04% -0.72% 0.83% 0.76% 0.66% 4.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -15.64% - - - 15.28% 17.52% 8.63% 28.05%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 39.03% 5.99% 3.83% 4.09% 4.69% 7.52%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 578.76% 57.44% 2.51% 24.80% 23.92% 25.29%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 49.84% 6.35% 5.62% 8.17% 6.15% 5.06%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,194.16% 122.70% 55.68% 44.42% 46.13% 41.47%
Earnings before Interest and Taxes (EBIT)		 -11 -12 -10 -16 -17 -15 -3.32 13 20 20 52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -12 -10 -16 -17 -15 -3.21 14 20 20 56
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.48 4.43 2.51 2.73 4.02 5.24 8.10 5.63 3.70 4.02 2.68
Price to Tangible Book Value (P/TBV)		 3.48 4.43 2.51 2.73 4.16 5.47 8.37 5.76 3.76 4.05 0.00
Price to Revenue (P/Rev)		 3,251.82 5,950.42 7,044.87 0.00 0.00 185.19 37.24 10.97 5.15 7.29 4.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.73 17.32 6.17
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.04% 5.77% 16.21%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 418.06 34.12 12.93 9.32 23.32 3.10
Enterprise Value to Revenue (EV/Rev)		 2,285.45 4,526.62 4,142.11 0.00 0.00 150.18 33.63 9.78 4.21 5.72 4.40
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.36 13.92 8.53
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.26 14.11 8.88
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.99 14.24 5.88
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.82 12.38
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 35.70 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01
Long-Term Debt to Equity		 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01
Financial Leverage		 -1.03 -1.05 -1.04 -1.08 -1.02 -1.03 -0.93 -0.83 -0.79 -0.89 -0.28
Leverage Ratio		 1.09 1.13 1.10 1.15 1.14 1.21 1.19 1.30 1.26 1.16 1.91
Compound Leverage Factor		 1.05 1.07 1.02 1.08 1.08 1.11 1.00 1.30 1.29 1.21 1.94
Debt to Total Capital		 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 1.01%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22%
Long-Term Debt to Total Capital		 0.00% 1.20% 0.66% 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.79%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 98.80% 99.34% 100.00% 99.18% 100.00% 100.00% 100.00% 100.00% 100.00% 98.99%
Debt to EBITDA		 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.04
Net Debt to EBITDA		 0.00 1.37 2.08 0.00 1.07 0.00 0.00 0.00 0.00 0.00 -0.69
Long-Term Debt to EBITDA		 0.00 -0.02 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.03
Debt to NOPAT		 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02
Net Debt to NOPAT		 0.00 1.95 2.96 0.00 1.52 0.00 0.00 0.00 0.00 0.00 -0.47
Long-Term Debt to NOPAT		 0.00 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02
Altman Z-Score		 14.93 9.35 11.25 4.51 7.19 4.10 9.61 5.92 6.24 16.74 1.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.15 7.39 11.61 6.97 6.65 4.79 3.96 3.39 4.21 7.82 1.94
Quick Ratio		 11.89 7.09 11.29 6.67 6.14 4.12 3.43 3.05 3.84 7.37 1.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.76 -7.69 -6.51 -8.86 -13 -14 -18 -26 -17 -10 -181
Operating Cash Flow to CapEx		 -70,390.67% -134,829.03% -84,894.78% -3,631.15% -28,235.89% -40,357.34% -139,769.68% -56,890.63% 193,932.43% 125,252.93% 6,100.85%
Free Cash Flow to Firm to Interest Expense		 -883.95 -1,314.10 -496.63 -1,351.17 -1,357.69 -2,154.45 -1,788.21 -2,597.87 -1,738.42 -1,544.21 -190.58
Operating Cash Flow to Interest Expense		 -1,184.35 -1,465.12 -663.27 -1,639.06 -1,760.07 -2,141.54 -1,364.04 -561.06 1,972.27 4,495.85 32.54
Operating Cash Flow Less CapEx to Interest Expense		 -1,186.04 -1,466.21 -664.05 -1,684.20 -1,766.30 -2,146.84 -1,365.01 -562.05 1,971.25 4,492.26 32.01
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.02 0.15 0.43 0.76 0.78 0.51
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.64 2.39
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66 0.81 0.78 0.69
Fixed Asset Turnover		 0.04 0.02 0.02 0.00 0.00 0.74 7.32 23.54 45.44 68.31 44.73
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.38 0.43 1.08 1.06 1.67 1.16 1.12
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 64.77 152.43
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 555.18 451.02 468.00 529.74
Days Payable Outstanding (DPO)		 263,507.26 525,271.11 1,867,035.68 0.00 952.68 858.02 337.83 343.19 218.86 314.16 324.68
Cash Conversion Cycle (CCC)		 -263,507.26 -525,271.11 -1,867,035.68 0.00 0.00 -858.02 -337.83 211.99 232.16 218.62 357.50
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.90 -2.94 -3.02 -6.07 -0.24 0.47 13 33 37 30 299
Invested Capital Turnover		 -0.03 -0.01 -0.01 0.00 0.00 -1.06 2.67 3.24 4.46 8.02 1.35
Increase / (Decrease) in Invested Capital		 0.05 -0.57 -0.81 -2.11 1.66 3.41 16 39 38 29 287
Enterprise Value (EV)		 132 165 123 115 175 196 429 425 347 695 928
Market Capitalization		 188 217 209 191 233 242 475 477 425 886 1,003
Book Value per Share		 $1.21 $1.08 $1.52 $1.28 $1.01 $0.80 $1.00 $1.44 $1.76 $3.25 $4.93
Tangible Book Value per Share		 $1.21 $1.08 $1.52 $1.28 $0.97 $0.77 $0.97 $1.41 $1.73 $3.22 ($0.44)
Total Capital		 54 50 84 70 58 46 59 85 115 221 378
Total Debt		 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00 0.00 0.00 3.81
Total Long-Term Debt		 0.00 0.59 0.56 0.00 0.48 0.00 0.00 0.00 0.00 0.00 2.97
Net Debt		 -56 -52 -86 -76 -58 -46 -46 -52 -78 -191 -75
Capital Expenditures (CapEx)		 0.01 0.01 0.01 0.30 0.06 0.03 0.01 0.01 0.01 0.02 0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.62 -5.25 -5.28 -8.06 -4.75 -3.53 8.64 29 33 26 71
Debt-free Net Working Capital (DFNWC)		 52 47 81 68 54 42 55 81 110 216 127
Net Working Capital (NWC)		 52 47 81 68 54 42 55 81 110 216 126
Net Nonoperating Expense (NNE)		 2.86 3.01 2.42 3.79 2.77 3.44 0.48 -0.53 -0.52 -0.79 -2.54
Net Nonoperating Obligations (NNO)		 -56 -52 -86 -76 -58 -46 -46 -52 -78 -191 -75
Total Depreciation and Amortization (D&A)		 0.05 0.05 0.05 0.05 0.06 0.11 0.11 0.17 0.20 0.20 3.71
Debt-free, Cash-free Net Working Capital to Revenue		 -6,266.32% -14,377.30% -17,776.99% 0.00% 0.00% -270.06% 67.73% 66.82% 39.94% 21.10% 33.71%
Debt-free Net Working Capital to Revenue		 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 60.16%
Net Working Capital to Revenue		 90,193.71% 129,350.11% 274,026.98% 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 59.76%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.25) ($0.17) ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42
Adjusted Weighted Average Basic Shares Outstanding		 44.09M 45.37M 56.55M 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.05) $0.00 $0.30 $0.28 $1.26
Adjusted Weighted Average Diluted Shares Outstanding		 45.38M 54.81M 54.81M 50.90M 54.96M 55.86M 58.83M 58.87M 68.98M 71.92M 86.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.38M 54.81M 54.81M 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.71 -8.26 -7.33 -11 -12 -11 -2.30 9.06 14 19 36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -820.03% -20.09% 29.49% 36.05% 47.92% 35.71%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 51.21% 52.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1,253.97 -2,019.82 -800.46 -2,389.80 -1,698.86 -2,334.09 -331.83 1,345.46 2,007.31 2,927.18 54.80
NOPAT to Interest Expense		 -878.76 -1,412.27 -558.77 -1,672.99 -1,188.91 -1,633.71 -229.95 1,292.70 2,011.12 2,854.54 111.81
EBIT Less CapEx to Interest Expense		 -1,255.65 -2,020.90 -801.25 -2,434.94 -1,705.09 -2,339.40 -332.81 1,344.47 2,006.29 2,923.59 54.27
NOPAT Less CapEx to Interest Expense		 -880.45 -1,413.36 -559.55 -1,718.13 -1,195.15 -1,639.01 -230.93 1,291.71 2,010.10 2,850.95 111.28
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

CorMedix (CRMD) has exhibited mixed results over the last four years, with a notable revenue spike in Q3 2025 and ongoing profitability volatility. Below are the key takeaways drawn from the quarterly cash flow, income statement, and balance sheet data provided (2022–2025).

  • Q3 2025 total revenue rose to 100,646,740 USD, marking a clear top-line acceleration from prior quarters.
  • Q3 2025 net cash from continuing operating activities was 30,693,811 USD, indicating solid cash flow from core operations in the quarter.
  • Q3 2025 basic earnings per share (EPS) was 1.42 and diluted EPS was 1.26, signaling a positive quarterly earnings reader for shareholders.
  • Liquidity remained strong as of Q3 2025: current assets 259,535,273 USD versus current liabilities 133,643,797 USD (roughly 1.9x current ratio).
  • Net cash from financing activities in Q3 2025 was 150,530,924 USD, largely supported by equity financing, aiding the company’s cash runway.
  • Q3 2025 gross margin was strong at about 93,080,673 USD on 100,646,740 USD revenue, roughly 92.4% gross margin.
  • Retained earnings remained negative but improved to about -190.6 million USD in Q3 2025 from roughly -336.9 million USD in earlier periods, indicating progress but ongoing deficits.
  • The substantial net income in Q3 2025 appears to be influenced by non-operating items and tax effects, so it may not reflect sustained operating profitability.
  • Trailing quarters show recurring net losses in multiple periods (e.g., Q2 2025 and Q1 2025 each posted notable losses), highlighting ongoing earnings volatility.
  • Investing cash outflows remained substantial, including about 291.3 million USD used in investing activities in Q3 2025, underscoring a continued heavy investment outlay that pressures near-term liquidity absent offsetting inflows.
05/18/26 02:42 PM ETAI Generated. May Contain Errors.

CorMedix Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CorMedix's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

CorMedix's net income appears to be on an upward trend, with a most recent value of -$17.93 million in 2024, falling from -$20.45 million in 2014. The previous period was -$46.34 million in 2023. Check out CorMedix's forecast to explore projected trends and price targets.

CorMedix's total operating income in 2024 was -$22.36 million, based on the following breakdown:
  • Total Gross Profit: $40.28 million
  • Total Operating Expenses: $62.64 million

Over the last 10 years, CorMedix's total revenue changed from $189.27 thousand in 2014 to $43.47 million in 2024, a change of 22,867.9%.

CorMedix's total liabilities were at $34.19 million at the end of 2024, a 186.9% increase from 2023, and a 2,236.4% increase since 2014.

In the past 10 years, CorMedix's cash and equivalents has ranged from $4.34 million in 2014 to $53.32 million in 2021, and is currently $40.65 million as of their latest financial filing in 2024.

Over the last 10 years, CorMedix's book value per share changed from 0.16 in 2014 to 1.44 in 2024, a change of 786.0%.


Related Companies

Financial statements for NASDAQ:CRMD last updated on 11/14/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ZENA Surges: 558% Revenue Growth Fuels Breakout Small-Cap Narrative!
ZenaTech (NASDAQ: ZENA) reported $12.9 million in full-year 2025 revenue, representing 558% year-over-year gro...
Equiscreen | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel